Cerus

Cerus

At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe.

Location
—
Roles tracked
0
In pipeline
0
Tracking since
—

At a glance

You're tracking 0 roles at Cerus. Track a role to start building momentum here.

Company intel

From the job board · LinkedIn data via posting sync
Industry
Biotechnology Research
Company size
382 people
Headquarters
Concord, California +1 more
Founded
1992
Type
Public Company
Total funding
$315.8M

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

blood safety pathogen inactivation hospital safety patient safety pandemic preparedness plasma pathogen reduction blood supply healthcare public health transfusion medicine platelets

Open roles at Cerus